FDA reschedules panel review of Cymbalta for chronic pain
This article was originally published in Scrip
Executive Summary
The US FDA's anaesthetic and life support drugs advisory committee is scheduled to review Lilly's proposed new use for Cymbalta (duloxetine) for the treatment of chronic pain on 19 August.